ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

F. Cardoso1*, A. Costa2,3, L. Norton4, E. Senkus5, M. Aapro6, F. André7, C. H. Barrios8, J. Bergh9, L. Biganzoli10, K. L. Blackwell11, M. J. Cardoso12, T. Cufer13, N. El Saghir14, L. Fallowfield15, D. Fenech16, P. Francis17, K. Gelmon18, S. H. Giordano19, J. Gligorov20, A. Goldhirsch21, N. Harbeck22, N. Houssami23, C. Hudis24, B. Kaufman25, I. Krop26, S. Kyriakides27, U. N. Lin26, M. Mayer28, S. D. Merjaver29, E. B. Nordström30, O. Pagani31, A. Partridge32, F. Penault-Llorca33, M. J. Piccart34, H. Rugo35, G. Sledge36, C. Thomssen37, L. van’t Veer38, D. Vorobiof39, C. Vrieling40, N. West41, B. Xu42 & E. Winer26 European School of Oncology & Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal; European School of Oncology, Milan, Italy; European School of Oncology, Bellinzona, Switzerland; Breast Cancer Program, Memorial Sloan-Kettering Cancer Centre, New York, USA; Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland; Division of Oncology, Institut Multidisciplinaire d’Oncologie, Genolier, Switzerland; Department of Medical Oncology, GustaveRoussy Institute, Villejuif, France; Department of Medicine, PUCRS School of Medicine, Porto Alegre, Brazil; Department of Oncology/Radiumhemmet, Karolinska Institutet & Cancer Center Karolinska and Karolinska University Hospital, Stockholm, Sweden; Department of Medical Oncology, Sandro Pitigliani Oncology Centre, Prato, Italy; Breast Cancer Clinical Program, Duke Cancer Institute, Durham, USA; Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal; University Clinic Golnik, Medical Faculty Ljubljana, Ljubljana, Slovenia; NK Basile Cancer Institute Breast Center of Excellence, American University of Beirut Medical Center, Beirut, Lebanon; Brighton & Sussex Medical School, University of Sussex, Falmer, UK; Breast Care Support Group, Europa Donna Malta, Mtarfa, Malta; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia; BC Cancer Agency, Vancouver, Canada; Departments of Health Services Research and Breast Medical Oncology, UT MD Anderson Cancer Center, Houston, USA; APHP Tenon, IUC-UPMC, Francilian Breast Intergroup, AROME, Paris, France; Program of Breast Health, European Institute of Oncology, Milan, Italy; Brustzentrum der Universität München, Munich, Denmark; Screening and Test Evaluation Program, School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia; Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, USA; Sheba Medical Center, Tel Hashomer, Israel; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Europa Donna Cyprus, Nicosa, Cyprus; AdvancedBC.org, New York; University of Michigan Medical School and School of Public Health, Ann Arbor, USA; Europa Donna Sweden & Bröstcancerföreningarnas Riksorganisation, BRO, Sundbyberg, Sweden; Oncology Institute of Southern Switzerland and Breast Unit of Southern Switzerland, Bellinzona, Switzerland; Department Medical Oncology, Division of Women’s Cancers, Dana-Farber Cancer Institute, Boston, USA; Jean Perrin Centre, Comprehensive Cancer Centre, Clermont Ferrand, France; Department of Medicine, Institut Jules Bordet, Brussels, Belgium; Department of Medicine, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; Indiana University Medical CTR, Indianapolis, USA; Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle an der Saale, Germany; Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA; Sandton Oncology Centre, Johannesburg, South Africa; Department of Radiotherapy, Clinique des Grangettes, Geneva, Switzerland; Nursing Division, Health Board, Cardiff and Vale University, Cardiff, UK; Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China